По вашему запросу найдено документов: 24

Страница 1 из 3

Pharmacokinetic Parameters of the Lappaconitine, Glycyrrhizic Acid and Methyluracil Combination Exhibiting Antiarrhythmic Properties upon Single Intragastric Administration in Various Dose
Kataev, V.A., Petrova, S.F., Perfilova, V.N., Murinov, Y.I., Bashkatov, S.A., Ivanov, S.P., Kataev, V.V., Agletdinov, E.F. (2021)
The pharmacokinetic properties of a finished dosage form (FDF) of a combination of lappaconitine
Biopharmaceutical Study of an Injectable Dosage Form of the New Antiaggregant Substance 3-Methyl-8-(Piperazin-1-yl)-7-(Thietan-3-yl)-1-Ethyl-1H-Purine-2,6(3H,7H)-Dione Hydrochloride
Smirnova, L. A., Spasov, A. A., Khaliullin, F. A., Kucheryavenko, A. F., Ryabukha, A. F., Abramov, O. K. (2021)
The pharmacokinetic parameters of the parent substance and the injectable dosage form of the new
РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ ФАРМАКОКИНЕТИКИ И ПРОДОЛЖИТЕЛЬНОСТИ ЭКСКРЕЦИИ МЕЛЬДОНИЯ ПО ПОКАЗАТЕЛЯМ СОДЕРЖАНИЯ В ПЛАЗМЕ КРОВИ И В МОЧЕ ЗДОРОВЫХ ДОБРОВОЛЬЦЕВ-СПОРТСМЕНОВ ПРИ ДЛИТЕЛЬНОМ ПРИЕМЕ БОЛЬШИХ ДОЗ ПРЕПАРАТА
COMPARATIVE DATA ON PHARMACOKINETICS AND THE DURATION OF THE EXCRETION WITH BLOOD AND URINE OF MELDONIUM IN HEALTHY ATHLETES - VOLUNTEERS AND HEALTHY TESTS VOLUNTEERS
РАБИН, О., УЙБА, В.В., МИРОШНИКОВА, Ю.В., ЗАБЕЛИН, М.В., САМОЙЛОВ, А.С., КАРКИЩЕНКО, В.Н., СЕМЕНОВ, С.Ю., АСТРЕЛИНА, Т.А., РАЗИНКИН, С.М., Rabin, O., Uyba, V.V., Miroshnikova, Yu.V., Zabelin, M.V., Samoilov, A.S., Karkishchenko, V.N., Semenov, S.Yu., Astrelina, T.A., Razinkin, S.M. (2019)
COMPARATIVE DATA ON PHARMACOKINETICS AND THE DURATION OF THE EXCRETION WITH BLOOD AND URINE
3-SUBSTITUTED THIETANE-1,1-DIOXIDES: SYNTHESIS, ANTIDEPRESSANT ACTIVITY, AND IN SILICO PREDICTION OF THEIR PHARMACOKINETIC AND TOXICOLOGICAL PROPERTIES
Klen, E.E, Nikitina, I.L., Makarova, N.N, Miftakhova, A.F, Ivanova, O.A, Khaliullin, F.A., Alekhin, E.K. (2017)
(mutagenicity, tumorigenicity, irritation, reproductive toxicity) and satisfactory pharmacokinetic
Биофармацевтическое исследование инъекционной лекарственной формы нового антиагрегантного вещества 3-метил-8- (пиперазин-1-ил) -7- (тиетан-3-ил) -1-этил- 1H- пурин-2,6 (3 H , 7 H ) -диона гидрохлорид
Biopharmaceutical Study of an Injectable Dosage Form of the New Antiaggregant Substance 3-Methyl-8-(Piperazin-1-yl)-7-(Thietan-3-yl)-1-Ethyl-1H-Purine-2,6(3H,7H)-Dione Hydrochloride
Smirnova, L.A., Spasov, A.A., Khaliullin, F.A., Kucheryavenko, A.F., Ryabukha, A.F., Abramov, O.K., Смирнова Л.А., Спасов А.А., Халиуллин, Кучерявенко А.Ф., Рябуха A.Ф., Абрамов О.К. (2021)
The pharmacokinetic parameters of the parent substance and the injectable dosage form of the new
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis
Ruperto, N, Brunner, HI, Pacheco-Tena, C, Louw, I, Vega-Cornejo, G, Spindler, AJ, Kingsbury, DJ, Schmeling, H, Borzutzky, A, Cuttica, R, Inman, CJ, Malievskiy, V, Scott, C, Keltsev, V, Terreri, MT, Viola, DO, Xavier, RM, Fernandes, TAP, Velazquez, MDM, Henrickson, M, Clark, MB, Bensley, KA, Li, XM, Lo, KH, Leu, JH, Hsu, CH, Hsia, EC, Xu, ZH, Martini, A, Lovell, DJ, Group Authors:Pediat Rheumatology Collaborative (Pediat Rheumatology Collaborative), Paediat Rheumatology Int Trials Or (Paediat Rheumatology Int Trials Or) (2021)
Objectives To assess efficacy, pharmacokinetics (PK) and safety of intravenous (i.v.) golimumab
A RANDOMIZED PHASE 2 STUDY OF LONG-ACTING TRANSCON GH VS DAILY GH IN CHILDHOOD GH DEFICIENCY
Chatelain, Pierre, Malievskiy, Oleg, Radziuk, Klaudziya, Senatorova, Ganna, Abdou, Magdy O., Vlachopapadopoulou, Elpis, Skorodok, Yulia, Peterkova, Valentina, Leff, Jonathan A., Beckert, Michael (2017)
the pharmacokinetics, pharmacodynamics, safety, and efficacy of weekly TransCon GH to that of daily GH in prepubertal
Novel O-benzylcinnamic acid derivative L26 treats acute lung injury in mice by MD-2
Li, Xiang, Yin, Lina, Liao, Jing, Yang, Jun, Cai, Binhao, Yu, Yiming, Su, Sijia, Du, Zhiteng, Li, Xiaobo, Zhou, Ying, Chen, Pan, Cho, Won-Jea, Chattipakorn, Nipon, Samorodov, Aleksandr V., Pavlov, Valentin N., Zhang, Fengzhi, Liang, Guang, Tang, Qidong (2023)
not cause adverse reactions in mice, and it was safe in vivo. Also, the preliminary pharmacokinetic
КЛИНИЧЕСКОЕ ТЕЧЕНИЕ КИШЕЧНОЙ ИНФЕКЦИИ НА ФОНЕ ДИССЕМИНИРОВАННОЙ ФОРМЫ ПСОРИАЗА
THE CLINICAL COURSE OF INTESTINAL INFECTIONS ON THE BACKGROUND OF DISSEMINATED FORMS OF PSORIASIS
Якупова, И.Х., Бурганова, А.Н., Куватова, Н.Д., Ширяев, А.П., Бердыев, А.С., Зубаирова, Г.Р., Файзулова, Г.И., Yakupov, I.H., Burganova, A.N., Kuvatova, N.D., Shiryaev, A.P., Berdyev, A.S., Zubairova, G.R., Faizullova, G.I. (2018)
is due to several factors: a decrease in local and General immunity, changes in the pharmacokinetics
LONG-ACTING C-TERMINAL PEPTIDE-MODIFIED HGH (MOD-4023): RESULTS OF A SAFETY AND DOSE-FINDING STUDY IN GHD CHILDREN
Zelinska, N., Iotova, V., Skorodok, J., Malievsky, O., Peterkova, V., Samsonova, L., Rosenfeld, Ron G., Zadik, Zvi, Jaron-Mendelson, Michal, Koren, Ronit, Amitzi, Leanne, Raduk, Dmitri, Hershkovitz, Oren, Hart, Gili (2017)
the safety, tolerability, pharmacokinetics/pharmacodynamics, and efficacy of three different weekly MOD-4023

Страница 1 из 3

Google Scholar
OpenDoar

Фасеты

Авторы
Ключевые слова
Год